Current filters:


Popular Filters

7940 to 7964 of 8757 results

Tranzyme Pharma extends drug discovery collaboration with Bristol-Myers Squibb


USA-based Tranzyme Pharma (Nasdaq: TZYM) says it has extended its chemistry-based drug discovery collaboration…

Bristol-Myers SquibbLicensingPharmaceuticalResearchTranzyme

Amgen shares jump as firm unveils plans for a $5 billion stock purchase


USA-based Amgen (Nasdaq: AMGN), the world’s largest independent biotech firm, saw its shares leap…


Will the USA’s Hatch-Waxman lock be sprung in 2012? asks HP&M lawyer


In the USA, there have been rumors for several weeks that, once the ball gets rolling in Congress with…

GenericsLegalNorth AmericaPharmaceuticalPoliticsRegulation

Recordati’s Normosang now approved in Russia; posts strong financials


Italian drugmaker Recordati (REC: MI) and wholly-owned subsidiary Orphan Europe announced that Normosang,…

EuropeFinancialNormosangPharmaceuticalRare diseasesRecordatiRegulation

Another call for reform of Canada’s pharma intellectual property laws


Canada's pharmaceutical intellectual property laws need major reform to encourage and protect innovation…

North AmericaPatentsPharmaceutical

South Korean govt to slash drug prices 14%


South Korea’s Ministry of Health and Welfare has issued an advance notice of the legislation of…


FDA accepts VIVUS NDA filing for Qnexa with PDUFA set for April 2012


There was good news for US drugmaker VIVUS (Nasdaq: VVUS) in its long-running battle to get its weight-loss…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

Added indication for Bristol-Myers’ Erbitux approved by FDA


The US Food and Drug Administration yesterday approved US drug major Bristol-Meyers Squibb’s (NYSE:…

Bristol-Myers SquibbErbituxNorth AmericaOncologyPharmaceuticalRegulation

Ph III study shows Novartis’ canakinumab substantially reduces steroid use in children with SJIA


Swiss drug major Novartis (NOVN: VX) says new pivotal Phase III data show that 45% of children with active…

Anti-Arthritics/RheumaticsCanakinumab InjectionIlarisNovartisResearch

Vertex’ Incivek set to break record for fastest product launch


Vertex Pharmaceuticals’ (Nasdaq: VRTX) new hepatitis C drug Incivek (telaprevir) is being touted…

FinancialIncivekMarkets & MarketingPharmaceuticalVertex

Novo Nordisk says DegludecPlus provides superior glycemic control vs Lantus


Denmark-based insulin giant Novo Nordisk (NVO: N) yesterday announced positive clinical results from…

DegludecDegludecPlusDiabetesLantusNovo NordiskPharmaceuticalResearchSanofi

Small-molecule cancer drug revenues set to reach $27.3 billion in 2015, predicts Visiongain


Rising disease prevalence, along with advances in pharmacotherapy and diagnostics, will stimulate the…

Markets & MarketingOncologyPharmaceutical

Study identifies factors linked with better medication response for treatment of juvenile arthritis


Among patients with juvenile idiopathic arthritis (JIA) who initiated treatment with the drug etanercept…


Pfizer returns rights to TNF-alpha targeting nanobodies to Ablynx


Shares of Belgian drug developer Ablynx [Euronext Brussels: ABLX] fell 18.2% to 2.93 euros in morning…


Teva to continue selling Viagra generic in Russia


Israel-basedTeva Pharmaceutical Industries (Nasdaq: TEVA) managed to avoid a high-profile confrontation…

DynamicoEuropeGenericsMarkets & MarketingPatentsPfizerPharmaceuticalReproductiveTeva Pharmaceutical IndustriesViagra

Takeda slashes full-year forecasts on Nycomed costs and yen strength


Takeda Pharmaceuticals (TYO: 4502), Japan’s largest drugmaker, posted flat results for the fiscal…

FinancialPharmaceuticalTakeda Pharmaceuticals

US Rep Bass introduces legislation to save taxpayer money under Medicaid


US Congressman Charles Bass (Republican, New Hampshire) has introduced bipartisan legislation in the…

GenericsLegalNorth AmericaPricing

European and international experts discuss the way forward in developing ophthalmology medicines


The European Medicines Agency assembled for the first time some 200 experts in eye diseases from Europe,…


Synthes acquisition by Johnson & Johnson delayed as EU Commission starts in-depth investigation


The planned $21.3 billion acquisition of orthopedic device maker Synthes (SYST: VX), which is listed…

Johnson & JohnsonMergers & AcquisitionsPharmaceuticalSynthes

Vertex’ Kalydeco marks a milestone in fight against cystic fibrosis


The oral drug ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other…

ivacaftorKalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

7940 to 7964 of 8757 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top